

Supplementary Material

Gut Microbiota and Transcriptome Dynamics in Every-Other-Day Fasting are Associated with Neuroprotection in Rats with Spinal Cord Injury

Junyu Wang ^{1†}, Xiaohua Zhao ^{2,3†}, Ruihan Zhou ^{2†},Meiyu Wang ^{4†}, Wu Xiang², Ming Li³, Runling Tang³,Zilong You ⁵, Jingqi Zheng ², Jiayu Li ⁶, Li Zhu ⁶, Jiaxin Gao ⁶,Huaqiang Li ⁶,Rizhao Pang ^{2*}, Anren Zhang ^{7*}

¹ State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China

² Department of Rehabilitation Medicine, General Hospital of Western Theater Command, Chengdu 610083, China

³ Department of Rehabilitation Medicine, The People's Hospital of Tongliang District, Chongqing 402560, China

⁴ Rehabilitation and Wellness Care Centre, Tian Fu College of Swufe, Chengdu 610083, China

⁵ Department of Biochemistry and Biophysics, School of Basic Medical Sciences, Peking University, Beijing 100191, China

⁶ School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China;

⁷ Department of Rehabilitation Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China

† These authors contributed equally to this work

*Correspondence: przprz17@126.com (R.P.); anren0124@163.com (A.Z.)



1 Supplementary Figures and Tables



Supplementary Figure 1. Rat model of spinal cord injury (SCI) and the effect of EODF treatment on locomotor recovery. (A) C5 unilateral SCI by clamping and ipsilateral forelimb paralysis.(B-D) Time course of locomotor functional recovery as assessed by grooming test,Horizontal ladder test and Cylinder rearing test. ****p < 0.0001 indicates AL-SCI group compared to Sham group; *p < 0.05, **p < 0.01, ****p < 0.0001 indicates EODF-SCI group compared to AL-SCI group.





Supplementary Figure 2. Dilution curves of fecal samples. (A) Release profile of ad libitum diet (AL)-Healthy and every-other-day fasting (EODF)-Healthy groups. (B) Release curves of the EODF-SCI group at different time points. (C) Release curves of the AL-SCI group at different time points. (D) Release curves of the AL-SHAM group at different time points.





Supplementary Figure3. Characteristics of gut microbiota phyla and genera between the AL-Healthy and EODF-Healthy group. (A) Comparison of the phylum level composition of gut microbiota for each sample between groups (n = 6 per group). (B) Comparison of the genus-level gut microbiota composition for each sample between groups (n = 6).



| Genus | AL-Healthy | EODF-Healthy | P value |
|--|------------|--------------|---------|
| Prevotellaceae UCG-003 | 21.04 | 6.70 | 0.000 |
| Lactobacillus | 3.43 | 8.82 | 0.000 |
| Bacteroides | 2.36 | 6.82 | 0.017 |
| Lachnospiraceae NK4A136 group | 5.57 | 3.57 | 0.002 |
| Lachnospiraceae UCG-008 | 5.34 | 0.97 | 0.000 |
| Prevotella 9 | 3.74 | 2.26 | 0.018 |
| [Eubacterium] coprostanoligenes group | 3.51 | 2.41 | 0.001 |
| Prevotellaceae NK3B31 group | 3.79 | 1.93 | 0.000 |
| Alloprevotella | 0.68 | 3.94 | 0.010 |
| Prevotella 1 | 0.12 | 4.47 | 0.013 |
| CM1G08 | 0.77 | 3.68 | 0.062 |
| Ruminococcus 1 | 1.59 | 0.90 | 0.000 |
| Prevotellaceae UCG-001 | 1.21 | 0.77 | 0.028 |
| Rikenellaceae RC9 gut group | 0.30 | 1.50 | 0.002 |
| Ruminiclostridium 9 | 1.14 | 0.64 | 0.000 |
| Veillonellaceae UCG-001 | 1.51 | 0.02 | 0.000 |
| Odoribacter | 0.35 | 1.05 | 0.024 |
| Catenibacterium | 0.50 | 0.89 | 0.006 |
| Enterobacter | 0.20 | 1.13 | 0.052 |
| Ruminococcaceae UCG-005 | 0.86 | 0.47 | 0.046 |
| Sphingomonas | 0.58 | 0.72 | 0.512 |
| Ruminococcaceae UCG-003 | 1.00 | 0.17 | 0.000 |

Table S1 Comparison of genus levels between the AL-Healthy and EODF-Healthy groups.



| Table S2-GO enrichment analysis associated with neuroprotection | | | | |
|---|------------|---|--|--|
| 1 Day | GO:0033209 | tumor necrosis factor-mediated signaling pathway | Nfkbia; Tnfrsf25; Nradd; Card14 | |
| | GO:0006955 | immune response | RT1-DOb; RT1-Da; Sbspon; Tnfrsf25; Nradd; Nfil3; Tlr9; LOC108348072 | |
| | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | Ins2; Sphk1; Tlr9; Cth; Card14 | |
| | GO:0032496 | response to lipopolysaccharide | Hpgd; Acp5; Nfkbia; Tnfrsf25; Entpd1; Nradd; Slc11a1; Cebpb | |
| 3 Day | GO:0002474 | antigen processing and presentation of peptide antigen via MHC class I | RT1-A1; RT1-A2; LOC100364500; RT1-CE4; RT1-M6-1; RT1-CE10 | |
| | GO:0032496 | response to lipopolysaccharide | Lbp; Ptger1; Ptger3; Socs3; Dcn; Arg1; Ngf; Dio2; Nfkbia; Pawr; Tnfrsf25; Irf3; Ccl2; Ccl5; Trpv4; Junb; Ccr7; Ptgs2; Cd14; F3; Hmgb2; Ltc4s; C5ar1; Cebpb; Il1rn; Serpine1 | |
| | GO:0006955 | immune response | Osm; RT1-A1; RT1-A2; Lat; LOC103690020; Sectm1b; LOC100364500; RGD1565355; RT1-CE4; Oas1b; Oas1g; Ms4a2; Tnfrsf25; Thbs1; Ccr1; Ccr7; Prg4; Cd36; Enpp3; Tlr9; Il1rn; RT1-CE10 | |
| | GO:0006954 | inflammatory response | Lat; Ptger1; Ptger3; Agtr2; Ngf; Nfkbiz; Agtr1a; Kng1; Ms4a2; Tnfrsf25; Thbs1; Ccl2; Ccl5; Ccl6; Ccr1; Ccr7; Ptgs2; Ager; Cd14; C3; Tlr8; Igfbp4; C5ar1; Il1rn; Spp1 | |
| 7 Day | GO:0006954 | inflammatory response | Calca; Selp; Ccrl2; Cxcl13; Ccl6; Sdc1; Ucn; LOC681410; Cd14; Cd6; Cd40; Hck; Cd8a; Cela1; Cyba; C5ar1 | |



| | GO:0045591 | positive regulation of regulatory T-cell differentiation | Pirb; Cd46; Lilrb4 | |
|-----------------------------------|------------|--|--|--|
| | GO:0042102 | positive regulation of T cell proliferation | Pirb; Il21; Cd4; Cd6; Cd46 | |
| | GO:0045954 | positive regulation of natural killer cell-mediated cytotoxicity | Slamf6; Klrk1; ll21 | |
| | GO:0007159 | leukocyte cell-cell adhesion | Calca; Selp; Itga5 | |
| | GO:0071347 | cellular response to interleukin-1 | Apoe; Adamts7; Mylk3; Ccl6; Cd40; Cebpb | |
| | GO:0002548 | monocyte chemotaxis | Calca; Folr2; Ccl6 | |
| 14 Day | GO:0055114 | oxidation-reduction process | Hpgd; Kmo; LOC103693015; Cyp4b1; Akr1b7; Tyrp1; LOC108348083 | |
| | GO:0032496 | response to lipopolysaccharide | Hpgd; Pf4; Kmo; Gnrh1 | |
| | GO:0006954 | inflammatory response | Pf4; Scn9a; Trpv1; Map2k3 | |
| | GO:0006955 | immune response | RT1-DMa; RT1-DMb; Pf4 | |
| | GO:0043065 | positive regulation of the apoptotic process | Hpgd; Clip3; Casp12; Trpv1 | |
| | GO:0048678 | response to axon injury | Musk; Map1b; Ltc4s; Tspo | |
| | GO:0060291 | long-term synaptic potentiation | Tnr; Musk; Grin2a | |
| | GO:0007416 | synapse assembly | Pcdhb2; Pclo; Map1b | |
| 28 | GO:0007189 | adenylate cyclase-activating G-protein coupled receptor signaling pathway | Gcgr; Galr1; Gpr26 | |
| Day | GO:0071320 | cellular response to cAMP | Hcn1; Serpina3n; Serpine1 | |
| | GO:0043525 | positive regulation of neuron apoptotic process | Musk; Itga1; Kcnma1 | |
| | GO:0071363 | cellular response to growth factor stimulus | Grin2a; Map1b; Serpine1 | |
| Table S4-KEGG enrichment analysis | | | | |
| 1 Day | rno04080 | Neuroactive ligand-receptor interaction | Agtr2; Gabrb2; Hcrtr2; Nmur2; RGD1560455; Trhr | |



| | rno04151 | PI3K-Akt signaling pathway | Col1a2; Col2a1; Col4a1; Col9a3; Ddit4; Egf; Ins2; Itga2b; Lama1; Lamb1; Sgk1 | |
|-----------|----------|---|--|--|
| | rno04658 | Th1 and Th2 cell differentiation | Cd4; Dll4; Nfkbia; RT1-DOb; RT1-Da | |
| | rno04514 | Cell adhesion molecules (CAMs) | Cd22; Cd4; Cldn19; Mpz; RT1-DOb; RT1-Da | |
| | rno04659 | Th17 cell differentiation | Cd4; Nfkbia; RT1-DOb; RT1-Da | |
| 3 Day | rno04115 | p53 signaling pathway | Ccnb1; Ccnb2; Cdk1; Rrm2; Serpine1; Thbs1 | |
| | rno04657 | IL-17 signaling pathway | Ccl2; Cebpb; Fosb; Fosl1; Nfkbia; Ptgs2 | |
| | rno04668 | TNF signaling pathway | Ccl2; Cebpb; Junb; Nfkbia; Ptgs2; Socs3 | |
| | rno04350 | TGF-beta signaling pathway | Dcn; E2f5; Fst; Rbl1; Thbs1 | |
| | rno04064 | NF-kappa B signaling pathway | Bcl2a1; Cd14; Lbp; Nfkbia; Ptgs2 | |
| | rno04620 | Toll-like receptor signaling pathway | Cd14; Lbp; Nfkbia; Spp1; Tlr8 | |
| | rno04068 | FoxO signaling pathway | Ccnb1; Ccnb2; Klf2; Plk1; Plk4; Sgk1 | |
| | rno04210 | Apoptosis | Bcl2a1; Birc5; Ctsc; Lmnb1; Nfkbia; Ngf | |
| | rno04658 | Th1 and Th2 cell differentiation | Cd4; Lat; Mapk11; Rbpjl | |
| | rno04620 | Toll-like receptor signaling pathway | Ccl5; Irf3; Mapk11; Tlr9 | |
| | rno04514 | Cell adhesion molecules (CAMs) | Cd4; RT1-A1; RT1-A2; RT1-CE10; RT1-CE4; RT1-M6-1 | |
| | rno04621 | NOD-like receptor signaling pathway | Ccl5; Irf3; Mapk11; Oas1b; Trpm2 | |
| | rno04514 | Cell adhesion molecules (CAMs) | Cd4; Cd40; Cd6; Cd8a; Cd8b; RT1-DMa; Sdc1; Selp | |
| | rno04612 | Antigen processing and presentation | Cd4; Cd8a; Cd8b; RT1-DMa | |
| 7 Day | rno04660 | T cell receptor signaling pathway | Cd3d; Cd4; Cd8a; Cd8b | |
| | rno04658 | Th1 and Th2 cell differentiation | Cd3d; Cd4; RT1-DMa | |
| | rno04064 | NF-kappa B signaling pathway | Bcl2a1; Cd14; Cd40 | |
| | rno04659 | Th17 cell differentiation | Cd3d; Cd4; RT1-DMa | |
| 14 Day | rno04514 | Cell adhesion molecules (CAMs) | PVR; RT1-DMa; RT1-DMb | |
| 28 | rno04080 | Neuroactive ligand-receptor interaction | Chrm2; Galr1; Glra1; Grin2a; Npffr1 | |
| Day | rno04151 | PI3K-Akt signaling pathway | Chrm2; Itga1; Itga11; Tnr | |